Dasatinib

Mild Cognitive Impairment

Mayo ClinicSmall moleculePhase 2Active

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 73/ 100

Competitive context

149 Active assets in the Mild Cognitive Impairment cohort.

Asset / Sponsor	Phase	Rating
Ginkgo Biloba Extract Xiyuan Hospital of China Academy of Chinese Medical Sciences	Phase 4	BBB
Rivastigmine Singapore General Hospital	Phase 4	BBB
Nicotine University of Southern California	Phase 2	BBB
Oxybutynin University of Alberta	Phase 4	BBB
Metformin Fudan University	Phase 4	BB

View all 50 →

Same molecule, other indications

Dasatinib is also rated in:

B-cell acute lymphoblastic leukemiaDormant

BB

Indicative ·

70 / 100

chronic myeloid leukemiaDormant

BB

Indicative ·

68 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

67 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.